Fig. 6
Synergistic and durable anti-tumor activity of combination therapy based on anti-LGALS3BP ADC 1959-sss/DM4 and immune check-point inhibitor anti-PD-1 in murine syngeneic neuroblastoma model. (A) Tumor growth expressed as tumor volume (mm3) from first treatment of NXS2 hLGALS3BP allografts in syngeneic A/J mice treated or not with anti-PD-1 (10 mg/kg; twice weekly; five total i.p. injections), naked 1959-sss (10 mg/kg; twice weekly; three total i.v. injections), ADC 1959-sss/DM4 (10 mg/kg; twice weekly; three total i.v. injections), or combination of 1959-sss and anti-PD-1, or combination of 1959-sss/DM4 and anti-PD-1. Blue and pink arrows indicate 1959-sss or 1959-sss/DM4 and anti-PD-1 treatments administration, respectively. 5 or 6 mice were considered per experimental group. (B) Kaplan-Meier curve showing probability of survival of mice bearing NXS2 hLGALS3BP allografts treated or not with anti-PD-1, 1959-sss, ADC 1959-sss/DM4, combination of 1959-sss and anti-PD-1, or combination of 1959-sss/DM4 and anti-PD-1 from first treatment. Log-rank (Mantel-Cox) test: *** p < 0.001